Amneal Pharmaceuticals, Inc. (AMRX)
21.38
-0.32
(-1.50%)
USD |
NASDAQ |
Nov 13, 16:00
21.38
0.00 (0.00%)
After-Hours: 19:59
Amneal Pharmaceuticals Enterprise Value : 10.78B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 10.78B |
| November 11, 2026 | 10.78B |
| November 10, 2026 | 10.67B |
| November 09, 2026 | 10.63B |
| November 06, 2026 | 10.24B |
| November 05, 2026 | 9.997B |
| November 04, 2026 | 10.17B |
| November 03, 2026 | 10.26B |
| November 02, 2026 | 10.34B |
| October 30, 2026 | 10.71B |
| October 29, 2026 | 10.66B |
| October 28, 2026 | 10.59B |
| October 27, 2026 | 10.69B |
| October 26, 2026 | 10.54B |
| October 23, 2026 | 10.32B |
| October 22, 2026 | 10.36B |
| October 21, 2026 | 10.26B |
| October 20, 2026 | 10.13B |
| October 19, 2026 | 9.965B |
| October 16, 2026 | 9.902B |
| October 15, 2026 | 9.927B |
| October 14, 2026 | 9.805B |
| October 13, 2026 | 10.04B |
| October 12, 2026 | 10.20B |
| October 09, 2026 | 10.16B |
| Date | Value |
|---|---|
| October 08, 2026 | 10.07B |
| October 07, 2026 | 10.07B |
| October 06, 2026 | 10.29B |
| October 05, 2026 | 10.31B |
| October 02, 2026 | 10.29B |
| October 01, 2026 | 10.21B |
| September 30, 2026 | 10.24B |
| September 29, 2026 | 9.190B |
| September 28, 2026 | 9.286B |
| September 25, 2026 | 9.053B |
| September 24, 2026 | 9.064B |
| September 23, 2026 | 8.912B |
| September 22, 2026 | 8.966B |
| September 21, 2026 | 9.177B |
| September 18, 2026 | 8.714B |
| September 17, 2026 | 8.577B |
| September 16, 2026 | 8.513B |
| September 15, 2026 | 8.056B |
| September 14, 2026 | 8.238B |
| September 11, 2026 | 8.171B |
| September 10, 2026 | 8.127B |
| September 09, 2026 | 8.248B |
| September 08, 2026 | 8.184B |
| September 04, 2026 | 8.309B |
| September 03, 2026 | 8.446B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| TG Therapeutics, Inc. | 10.01B |
| Pfizer Inc. | 213.03B |
| Liquidia Corp. | 4.988B |
| Johnson & Johnson | 709.89B |
| Eli Lilly & Co. | 1.388T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 12.31M |
| Revenue (Quarterly) | 862.68M |
| Total Expenses (Quarterly) | 884.38M |
| EPS Diluted (Quarterly) | -0.0646 |
| Gross Profit Margin (Quarterly) | 38.73% |
| Profit Margin (Quarterly) | 1.43% |
| Earnings Yield | 1.91% |
| Operating Earnings Yield | 7.45% |
| Normalized Earnings Yield | 2.542 |